Nutriflex Omega Special Novo

Valine, Alanine, Arginine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine and Threonine, the active ingredients in Nutriflex Omega Special Novo, are an amino acid solution presented as an intravenous solution for intravenous use. It supplies essential amino acids to support protein synthesis and maintain nitrogen balance in patients who cannot receive enteral feeding, such as those in critical care, post‑operative or trauma settings, and individuals with severe malnutrition.

GNH USA supplies Nutriflex Omega Special Novo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nutriflex Omega Special Novo is used in the clinical management of patients requiring parenteral nutrition to meet protein and amino acid needs.

- Parenteral nutrition: Provides essential amino acids for patients who cannot receive enteral feeding. - Post‑operative or trauma care: Supplies amino acid supplementation to support tissue repair and recovery. - Malnutrition or catabolic states: Delivers intravenous protein support to maintain nitrogen balance in severely undernourished patients.

Adverse reactions may occur with any intravenous amino acid solution. Monitoring and appropriate management are essential.

Common Side Effects: - Infusion site pain or erythema - Nausea or vomiting - Mild hyperglycemia - Electrolyte disturbances (e.g., mild hypokalemia) - Transient fever or chills - Headache

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Metabolic acidosis - Hyperammonemia - Severe electrolyte imbalance (e.g., hyperkalemia) - Renal dysfunction or failure - Hepatic dysfunction or elevated liver enzymes

When using Nutriflex Omega Special Novo, clinicians should observe the following precautions.

- Monitor plasma electrolytes: Check sodium, potassium, and calcium levels regularly. - Assess renal and hepatic function: Adjust therapy in patients with impaired kidney or liver function. - Adjust dose in metabolic disorders: Reduce or modify infusion in patients with urea cycle defects or hyperammonemia. - Use aseptic technique: Prevent contamination during preparation and administration. - Avoid in known hypersensitivity: Discontinue if an allergic reaction occurs. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid): - Concurrent high‑dose potassium chloride: May cause dangerous hyperkalemia. - Co‑administration with other amino acid solutions: Can lead to excess nitrogen load. - Use with nephrotoxic agents: Increases risk of renal impairment.

Moderate Interactions (Monitor Closely): - Insulin therapy: May alter glucose control, requiring monitoring. - Corticosteroids: Can increase protein catabolism, affecting amino acid balance. - Diuretics: May exacerbate electrolyte disturbances, necessitating regular checks.